Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Clin Investig (Lond). 2012;2(2):163–175. doi: 10.4155/cli.11.174

Figure 3. Cystic fibrosis lung disease therapeutic targets.

Figure 3

Physiological ramifications of reduced CFTR activity in the cystic fibrosis lung are highlighted by large arrows. Therapeutic classes that have been and/or are being investigated for the chronic management of cystic fibrosis lung disease are shown in boxes, including CFTR gene therapy [127,128], small-molecule CFTR modulators [34,35,81-84], ion channel recruiters [36], hydrators [30,53], mucolytics [25], anti-infectives [27,31-33,52], vaccines [129] and anti-inflammatories [26,47,50]. Despite different mechanisms of action, all share the goal of reducing lung disease damage caused by the interplay of obstruction, infection and inflammation.